Powder: -20°C for 3 years | In solvent: -80°C for 1 year
RD162 is a non-steroidal antiandrogen (NSAA) specifically binding to the androgen receptor (AR).
パッケージサイズ | 在庫状況 | 単価(税別) | |||
---|---|---|---|---|---|
サンプルについてお問い合わせ | |||||
1 mg | 在庫あり | ¥ 9,000 | |||
5 mg | 在庫あり | ¥ 28,000 | |||
10 mg | 在庫あり | ¥ 45,500 | |||
25 mg | 在庫あり | ¥ 95,000 | |||
50 mg | 在庫あり | ¥ 141,500 | |||
100 mg | 在庫あり | ¥ 201,000 | |||
1 mL * 10 mM (in DMSO) | 在庫あり | ¥ 34,000 |
説明 | RD162 is a non-steroidal antiandrogen (NSAA) specifically binding to the androgen receptor (AR). |
In vitro | RD162 has little to no binding to the progesterone, estrogen, or glucocorticoid receptors. RD162 (1-10 μM) suppressed growth and induces apoptosis in the human prostate cancer cell line VCaP which had endogenous AR gene amplification[1]. |
In vivo | RD162 (20 mg/kg) is ∼50 percent bioavailable after oral delivery with a serum half-life of about 30 hours. RD162 (10 mg/kg; oral gavage) causes all tumors regressed. RD162 (0.1, 1, 10 mg/kg; oral gavage) consistently reduces luciferase activity with 10 mg/kg/day human LNCaP/AR xenografts grown in castrated male mice whereas lower doses of 0.1 and 1.0 mg/kg/day has minimal effect. RD162 substantially reduces cellular proliferation after 5 days[1]. |
分子量 | 476.45 |
分子式 | C22H16F4N4O2S |
CAS No. | 915087-27-3 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 50 mg/mL (104.94 mM)
You can also refer to dose conversion for different animals. 詳細
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
RD162 915087-27-3 Endocrinology/Hormones Androgen Receptor inhibit prostate VCaP Inhibitor castration RD 162 NSAA RD-162 LNCaP diarylthiohydantoin orally inhibitor